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Abstract L-type Ca2 channels play a critical role in many
types of cells, including nerve, muscle and endocrine cells. The
most popular and e¡ective tools for analyzing the roles of
L-type calcium channels (L-channels) are speci¢c antagonists
such as dihydropyrigines. With these drugs however, it is di⁄-
cult to target speci¢c cells. One solution is to develop a genet-
ically targetable inhibitor coded by DNA. As a candidate for
such an inhibitor, a dominant negative mutant of Cav1.2 was
designed by mimicking an ascidian 3-domain-type K1 subunit
(that inhibits the full-length subunit’s current). The 3-domain-
type Cav1.2 subunit signi¢cantly inhibited wild-type Cav1.2 cur-
rent, but not other ionic currents such as Cav2.1 and Nav chan-
nels in Xenopus oocyte expression systems. Western blot anal-
ysis showed that the expression of the wild-type protein into the
plasma membrane was signi¢cantly suppressed on coexpression
with the truncated protein. These ¢ndings support that an N-ter-
minus-truncated mutant could serve as a speci¢c genetically
encoded inhibitor for L-channels.
- 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
L-type voltage dependent calcium channels are distributed
broadly [1,2], and have many roles in cell functions [3], in-
cluding gene expression [4^6], learning and memory [7]. There
are speci¢c drugs for L-type calcium channels (L-channels)
such as dihydropyrigine, phenylalkylamines [8] and
FPL64176 [9]. These reagents serve as important tools to an-
alyze the roles of L-channels. However, L-channels exist in
many types of cells. It is therefore di⁄cult to de¢ne their roles
in vivo using these drugs. Knock out mice of L-channel K1
subunit genes have already been reported [10]. However, the
knocking out of Cav1.2 in mice is fatal. A new method needs
to be established to overcome such problems.
We designed here a dominant negative mutant of the
L-channel based on a recent ¢nding in the ascidian Ca2þ
channel; a 3-domain-type variant of the calcium channel K1
subunit TuCa1 had a signi¢cant inhibitory e¡ect on the ex-
pression of the full-length calcium channel current both in a
Xenopus oocyte expression system and ascidian native cells
[11]. Since TuCa1 is closely related to L-channels, we designed
a similar deletion in the Cav1.2 mutant by referring to this
truncated isoform. We found that the 3-domain-type Cav1.2
(vCav1.2) mutant has a strong inhibitory e¡ect on the wild-
type Cav1.2 channel current. This inhibition was speci¢c to
Cav1.2, since it did not a¡ect the current activity of Nav
channels and Cav2.1. We thus propose that the dominant
negative Cav1.2 mutant will serve as a useful molecular tool
for future studies on L-type Ca2þ channels.
2. Materials and methods
2.1. DNA construction
For optimizing translation, KOZAK core sequence [12] was in-
serted just before the ¢rst Met of the K1 subunits.
A full-length Cav1.2 cDNA [13] was subcloned into a Xenopus ex-
pression vector, pSD64TR, at KpnI and NotI sites. vCav1.2 was de-
signed as in Fig. 1. The 5P-side was ampli¢ed using Pfu polymerase
(Stratagene) and was joined to the 3P-part of the Cav1.2 subunit at the
EcoRI site. A stop codon was introduced into the 3-domain-type mu-
tant (stopvCav1.2), as shown in Fig. 4a. A DNA fragment around
¢rst Met and stop codon was obtained using Pfu polymerase and
joined to the 3P DNA fragment of Cav1.2.
The 5P-regions containing putative initial methionines of both the
full-length and vCav2.1 cDNA were ampli¢ed by Pfu polymerase,
were connected to the 3P part of the Cav2.1 subunit at the HindIII
site, and were subcloned into pSD64TR at KpnI and EcoRV sites.
2.2. RNA injection for Xenopus oocytes
Plasmids containing channel subunit cDNA were linearized with
SalI (most of cDNAs) or NotI (L2b and Nav1.4) and transcribed
with SP6 (most of cDNAs) or T7 (L2b) RNA polymerase for injection
into Xenopus oocytes.
Xenopus oocytes were prepared as described [14]. Synthetic RNA of
K1 subunits was injected into an oocyte at a concentration of 0.25 ng/
nl. L2b and K2N subunits of the rabbit Ca2þ channel were simulta-
neously injected at 0.25 ng/nl. In the experiments of coexpression with
Nav1.4 RNA, concentrations were 0.15 ng/nl W1, 0.2 ng/nl K1, L2b
and K2N. RNA concentrations were modi¢ed as shown in the ¢gure
legends. The volume of RNA solution injected into each oocyte was
50 nl. Injected oocytes were cultured at 18‡C. The amount of cRNA
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was roughly adjusted based on the concentration estimated by ethid-
ium bromide staining following RNA electrophoresis. All cRNA in-
jections contained L2b and K2N. Oocytes from the same batch were
recorded within about 5 h between 2 and 4 days after injection.
2.3. Electrophysiology of Xenopus oocytes
Electrical recordings of Xenopus oocytes were made as described in
[11].
The solutions used for recording Ba2þ currents consisted of 20 mM
Ba(OH)2, 35 mM NaOH, 77 mM methansulfonate, 2 mM KOH, and
5 mM HEPES (pH 7.4); or 5 mM Ba(OH)2 and 65 mM NaOH. The
solution for recording Naþ currents consisted of 96 mM NaCl, 1 mM
MgCl2, 2 mM KCl and 5 mM HEPES (pH 7.4). Linear leaks were
determined by measuring holding currents. Recordings with large lea-
kages (s 200 nA at 370 mV) were discarded. Results are presented as
the meanMS.E.M. (error bars in the ¢gures).
2.4. Transient expression of Cav1.2 subunits in BHK6 cells
Full-length and vCav1.2 were transiently expressed in BHK6 cells
[15]. Cell cultures and DNA transfections were carried out as de-
scribed in [16].
2.5. Whole-cell patch clamp recording
The whole-cell L-type channel currents were recorded with 2 mM
Ca2þ or 10 mM Ba2þ as a charge carrier in a bath solution containing
137 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 10 mM glucose, 10 mM
HEPES, and 2 mM CaCl2 (pH 7.4) at room temperature. The resis-
tance of the microelectrodes ranged from 1.5 to 4 M6 when ¢lled with
110 mM cesium methanesulfonate, 20 mM TEA, 14 mM EGTA,
5 mM MgATP, 5 mM disodium creatine phosphate, 0.2 mM GTP,
and 10 mM HEPES (pH 7.3). Currents were measured as described in
[16]. Results are presented as the meanMS.E.M. Statistical signi¢-
cance was assessed with the Student^Welch unpaired t-test. Di¡er-
ences at P6 0.05 were considered to be signi¢cant.
2.6. Western blotting
At 36 h after transfection, cells cultured in 35 mm dishes were
incubated on ice for 5 min by replacing with 180 Wl of Triton
X-100 bu¡er containing 10 mM Tris^Cl (pH 7.4), 5 mM EGTA,
5 mM EDTA, 120 mM NaCl, 1% (or 0.1%) Triton X-100, 200 nM
PMSF, 2 WM leupeptin, and 3 WM pepstatin A. Cells were then mixed
and incubated on ice for 5 min. Cell lysates were separated by spin-
ning. Supernatant (150 Wl) was added to 4USDS loading bu¡er (50
Wl). The pellet was added to 1% Triton X-100 bu¡er (180 Wl) and
4USDS loading bu¡er (60 Wl) and incubated at 37‡C for 20 min,
then loaded for SDS^PAGE. The rabbit polyclonal antibody CT4
was made to target the C-terminal (aa 2027^2143) of the Cav1.2 sub-
unit.
3. Results
3.1. vCav1.2 inhibited functional expression of
full-length Cav1.2
To make a Cav1.2 dominant negative mutant, we referred
to the sequence of the ascidian calcium channel (Fig. 1). Our
previous study showed that a truncated variant of the ascidian
L-type-like Ca2þ channel TuCa1 starting from the second
domain IIS2 works as the suppressor of functional expression
of the full-length protein. We suspected that a similar deleted
form of mammalian Cav channel may exhibit such inhibition.
We thus made a 3-domain-type K1 mutant starting from the
corresponding Met (Fig. 1, asterisked Met).
To test the inhibitory e¡ect of the vCav1.2 and vCav2.1,
full-length K1 cRNAs were coexpressed with or without
3-domain-type mutants. vCav1.2 inhibited almost completely
the wild-type Cav1.2, while vCav2.1 had no e¡ect on Cav1.2
(Fig. 2). On the other hand, vCav1.2 had no strong inhibitory
activity against the P/Q-type calcium channel subunit Cav2.1
(Fig. 2a,c). The experiments were repeated four times using
other batches of oocytes and similar results were obtained.
3.2. General translation was normal during the inhibition of
Cav currents by truncated mutants
To test the possibility that the combination of Cav1.2 and
vCav1.2 has a strong inhibitory e¡ect on general protein syn-
thesis in Xenopus oocytes, we examined the Naþ channel cur-
rent derived from the rat Nav1.4 gene when either coexpressed
or not with Cav1.2 channel subunits. At 20 ms depolarization,
Naþ current traces were similar among cells injected with Naþ
channel Nav1.4 only, with Nav1.4 plus Cav1.2, and with
Nav1.4, Cav1.2 plus vCav1.2 (Fig. 3), suggesting that
vCav1.2 does not suppress general translation in oocytes.
The experiments were repeated twice using other batches
with similar results.
3.3. Inhibition by vCav1.2 occurred after translation
It is possible that vCav1.2 inhibits Cav1.2 expression
Fig. 1. Peptide sequences of ascidian (TuCa1) and mammalian
(Cav2.1, Cav1.2) calcium channel K1 subunits around the IIS2 re-
gion. vNTuCa1 starts from the Met indicated by asterisks. Other
mutants were designed to start from the same position.
Fig. 2. Biophysical studies of suppressive e¡ect by vCav1.2 in Xeno-
pus oocytes. vCav1.2 signi¢cantly reduces expression of Cav1.2.
a: Representative traces of Ba2þ currents from oocytes injected with
each combination of cRNA as indicated. b: I^V relations of Ba2þ
currents from cells only expressing Cav1.2 (triangle; n=7), those co-
expressing Cav1.2 and vCav1.2 (rectangle; n=7) and those only ex-
pressing auxiliary subunits (circle; n=6). c: Comparison of maxi-
mum amplitudes of Ba2þ currents among oocytes expressing various
combinations of subunits.
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through RNA^RNA interaction. Alternatively, it may have
an inhibitory e¡ect at the protein level. To distinguish be-
tween these two possibilities, we introduced a stop codon
into vCav1.2 just after the initial Met (Fig. 4a), retaining all
the downstream sequence of vCav1.2 (stopvCav1.2).
StopvCav1.2 did not exhibit an inhibitory e¡ect like
vCav1.2 (Fig. 4b). This indicates that inhibition by vCav1.2
should occur at a step after the translation, not at the RNA
level.
3.4. vCav1.2 prevented the full-length protein from appearing in
membrane fractions
To gain insight into the molecular mechanism of inhibition
by vCav1.2, we used a transient DNA transfection system. We
utilized a mammalian cell line (BHK-6 cells) instead of Xeno-
pus oocytes for this experiment, because we could not reliably
detect Cav1.2 protein from Xenopus oocyte by Western blot
analysis. First, we checked whether inhibition of the full-
length channel activity by vCav1.2 also occurs in BHK-6 cells,
which stably express rabbit L1a and K2N subunits. Patch
clamp recordings showed that coexpression with vCav1.2
markedly reduced the amount of current derived from the
full-length Cav1.2 (Fig. 5a,b). By Western blotting of the Tri-
ton X-100 soluble fraction of cells of the same batches used
for electrophysiology, Cav1.2 immunoreactivity was shown to
be greatly reduced on coexpression with vCav1.2. This inhi-
bition seemed dose-dependent: three times more vCav1.2 sig-
ni¢cantly reduced the immunoreactivity of the full-length
Cav1.2. Unexpectedly, the immunoreactivity of vCav1.2 was
much weaker than the band of full-length Cav1.2 even though
vCav1.2 was transfected with a three-fold excess of DNA
(Fig. 5c). In addition, the immunoreactivity of vCav1.2 in
Fig. 3. Absence of inhibition of sodium channel expression. a: Rep-
resentative traces of Nav1.4 Naþ currents from Xenopus oocytes.
b: Comparison of maximum amplitudes of Naþ currents.
Fig. 4. cRNA having a stop codon just after the ¢rst Met did not
inhibit Cav1.2 channel current. a: N-terminal DNA sequence of
vCav1.2. A point mutation (lower ‘A’) was introduced. b: Maxi-
mum amplitudes of Ba2þ currents among oocytes. Concentrations
of injected cRNAs were, 0.2 ng/nl for Cav1.2, and 0.3 ng/nl for
stopvCav1.2 and vCav1.2.
Fig. 5. The suppression of Ca2þ channel activity and protein expres-
sion by vCav1.2 in BHK6 cells. a: Coexpression of vCav1.2 caused
signi¢cant suppression of L-channel current. Representative traces
recorded from cells transfected with DNAs as indicated. Ca2þ chan-
nel current traces were recorded with 2 mM Ca2þ(black) or 10 mM
Ba2þ(gray). b: Current densities of Ca2þ or Ba2þ current. Asterisks
indicate P6 0.01. c: vCav1.2 suppressed the expression of Cav1.2.
BHK6 cells were transfected with Cav1.2 plus pcDNA3 or vCav1.2
at a molar ratio of 1:1 or 1:3. Soluble fractions of cell lysates were
analyzed with anti-CT4 antibody. d: Low solubility of vCav1.2.
BHK6 cells indicated by Western blot, transfected as indicated at a
molar ratio of 1:3, were harvested. Triton X-100 soluble (S) and in-
soluble (I) fractions were analyzed with anti-Cav1.2 CT4 antibody.
A non-speci¢c band slightly overlapped the signal for vCav1.2 in
the soluble fraction (c,d). Note that the increased intensity of the
band on transfection of vCav1.2 which indicates the presence of
vCav1.2.
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cells transfected with vCav1.2 alone was less than that of
Cav1.2 (data not shown). To check the possibility that
vCav1.2 is expressed in the insoluble fraction, we harvested
the cells on altering Triton X-100 concentrations, and ana-
lyzed Cav1.2 channel immunoreactivity in the insoluble frac-
tion. This analysis indicated that the vCav1.2 subunit tended
to exist in the insoluble fraction. The immunoreactivity of the
full-length Cav1.2 in the soluble fraction decreased when
vCav1.2 was coexpressed as already shown (Fig. 5c). In con-
trast, Cav1.2 in the insoluble fraction with 1% Triton X-100
increased when vCav1.2 was coexpressed (Fig. 5d). In the
soluble fractions, there was a non-speci¢c band slightly over-
lapping with the signal for vCav1.2 (Fig. 5c,d). However, the
existence of vCav1.2 was evident from the increased intensity
of the band on transfection of vCav1.2, as compared with
transfection of the vehicle vector alone.
3.5. vCav2.1 did not act as a dominant negative mutant
To know whether a truncated protein lacking an N-termi-
nus and the ¢rst domain of other classes of Ca2þ channels
also show similar negative e¡ect, we made a similar 3-domain
mutant for Cav2.1 (Fig. 1). However, this mutant caused little
inhibition of the full-length Cav2.1 current (Fig. 6). There was
still no strong inhibition even when three-times excess amount
of vCav2.1 cRNA was injected. Similar results were obtained
for Cav3.1 in HEK cells (data not shown). Therefore, suppres-
sion by vCav1.2 may be mediated by mechanisms unique to
Cav1.2.
4. Discussion
In this study, we designed an inhibitory subunit of Cav1.2
by mimicking an endogenous calcium channel subunit of as-
cidian embryos which strongly suppresses the functional ex-
pression of the full-length protein [11]. This subunit (vCav1.2)
signi¢cantly inhibited Cav1.2 channel current in a subtype-
speci¢c manner (Fig. 2). Moreover, the inhibition by
vCav1.2 had no e¡ect on the expression of the Naþ channel
(Fig. 3), indicating that it is not mediated by inhibition of the
general translational machinery. Since the insertion of a pre-
mature stop codon into vCav1.2 led to a loss of the e¡ect, the
inhibition must occur at the protein level (Fig. 4). Western
blot analysis indicated that the coexpression of vCav1.2 re-
duced the expression of full-length Cav1.2 in the Triton X-100
soluble fraction (including the plasma membrane) (Fig. 5). A
similar deletion construct for another class of calcium chan-
nel, Cav2.1 however, had no strong inhibitory e¡ect on the
full-length Cav2.1 current (Fig. 6), suggesting that inhibition
of the full-length-derived current by the 3-domain-type K1
subunit occurs via a mechanism unique to Cav1 class chan-
nels.
Familial episodic ataxia type 2 is an autosomal dominant
paroxysmal cerebral disorder. Some types of this disorder are
caused by one base mutation of the Cav2.1 gene [17,18]. This
mutation results in the translation of a truncated form of
Cav2.1 consisting of the I, II and a part of the III domain.
Recently, truncated subunits consisting of domains I and II or
domains III and IV of Cav2.2 have been reported to work as
dominant negative [19]. Cav2.2 mutants are expressed and
e¡ect on protein synthesis or protein folding of wild-type
channels. In our case, the 3-domain-mutant of Cav2.1 and
Cav3.1 did not show a signi¢cant inhibitory e¡ect on wild-
type channels. Therefore, the mechanism of 3-domain-mutant
of Cav1.2 should be di¡erent from the other Cav dominant
negative e¡ects. L-Subunit is needed for the e¡ective expres-
sion of current. It is unlikely that vCav1.2 scavenges the
L-subunit, because it lacks a L-subunit binding region in the
I^II loop [20]. Another line of evidence indicates that this
inhibition is subtype-speci¢c: vCav1.2 did not inhibit Cav2.1
current.
Truncated Kþ channels often show dominant negative ef-
fects. This can be accounted for by inhibition of coassembly
or insertion into the plasma membrane [21]. A similar inter-
pretation does not apply to the Cav channel however, because
a single Cav subunit forms a single pore. Nevertheless, sup-
pression of the full-length protein by vCav1.2 suggests that
some cooperative interaction among homogenous channels is
required for e⁄cient channel assembly or expression. Immu-
nostaining analysis revealed that L-channels are clustered in
cell bodies and proximal dendrites in neurons [22]. Recently, a
single channel imaging study of Cav1.2 suggested that Cav1.2
molecules form clusters as K1 subunit themselves through self-
aggregation [23]. These ¢ndings are consistent with the above-
mentioned idea.
Our vCav1.2 mutant inhibits speci¢cally Cav1.2 channel
current. Although the mechanisms of suppression require fur-
ther study, this mutant will be potentially useful for analyzing
the roles of L-channels. We are currently making transgenic
mice which express this vCav1.2 mutant only in certain types
of neurons to better de¢ne the role of the L-channel in neural
development and function.
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Fig. 6. vCav2.1 mutant did not work as a dominant negative mu-
tant. a: Representative traces of Ba2þ currents from Xenopus oo-
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or 0.45 ng/nl for vCav2.1, 0.15 ng/nl for L2b and 0.15 ng/nl for
K2N.
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